Pediatric antimicrobial stewardship in the COVID-19 outbreak

To the Editor—Growing evidence supports the positive impact of antimicrobial stewardship programs (ASPs) on antimicrobial use, including pediatrics.1 Although short of the level of acceptance these have reached in the United States, the implementation of pediatric ASPs in European hospitals has incr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Infection control and hospital epidemiology 2021-05, Vol.42 (5), p.642-644
Hauptverfasser: Velasco-Arnaiz, Eneritz, López-Ramos, Maria Goretti, Simó-Nebot, Silvia, Jordan, Iolanda, Ríos-Barnés, María, Urrea-Ayala, Mireia, Monsonís, Manuel, Fortuny, Clàudia, Noguera-Julian, Antoni
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 644
container_issue 5
container_start_page 642
container_title Infection control and hospital epidemiology
container_volume 42
creator Velasco-Arnaiz, Eneritz
López-Ramos, Maria Goretti
Simó-Nebot, Silvia
Jordan, Iolanda
Ríos-Barnés, María
Urrea-Ayala, Mireia
Monsonís, Manuel
Fortuny, Clàudia
Noguera-Julian, Antoni
description To the Editor—Growing evidence supports the positive impact of antimicrobial stewardship programs (ASPs) on antimicrobial use, including pediatrics.1 Although short of the level of acceptance these have reached in the United States, the implementation of pediatric ASPs in European hospitals has increased over the last few years.1 It has been suggested that the ASP should be helpful in the preparation for and response to the SARS-CoV-2/COVID-19 outbreak,2 but no formal recommendations have been published. From March 16 to April 30 2020, 210 randomly selected prescriptions were assessed for quality.3 Because SARS-CoV-2 is a viral infection, it is not expected to directly influence antibiotic or antifungal use beyond the use of antibiotics with possible antiviral effect (ie, azithromycin)4 and the use of broad-spectrum antibiotics for superinfection in severe COVID-19 patients.5 However, we also observed antimicrobial use changes indirectly related to the outbreak. New COVID-19 protocols are constantly updated in accordance with newly available information, and previous protocols have been temporarily modified in favor of medical nonsurgical management of some conditions (eg, noncomplicated appendicitis).7 Our data show that the SARS-CoV-2 pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population; pediatric ASP monitoring and interventions remain useful to preserve the quality of prescriptions, at least in the short term. Planning the response to epidemic waves should include the widespread integration of ASP, with (1) involvement of the ASP team in guidelines development as exemplified in “Multicenter Initial Guidance on Use of Antivirals for Children with COVID-19/SARS-CoV-2”8; (2) integrated response of common ASP local and external partnerships and infrastructures, including structured interviews, formularies, and other information technology tools9; and (3) coordination of indicator selection and monitoring routines to support a continuous evaluation strategy.
doi_str_mv 10.1017/ice.2020.312
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7338437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2732485119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-90031d7b7b743c1a490eff90533d0bc82ab174ee38a2e95021f1f8e7960744703</originalsourceid><addsrcrecordid>eNpdkc9r1UAQxxdR7Gv15lkCXjw0z5mdTXYXRJDnjxYK9aDibdkkE9_WvOR1N6n433dLa9EyhznMhy8z8xHiBcIaAfWb0PJagoQ1oXwkVlhVtqwNqcdiBcba0kj6cSAOU7oAAG0tPhUHJCtdS2tW4u0X7oKfY2gLP85hF9o4NcEPRZr5t49d2oZ9EcZi3nKxOf9--qFEW0zL3ET2v56JJ70fEj-_60fi26ePXzcn5dn559PN-7OyraieSwtA2Okml6IWvbLAfW-hIuqgaY30DWrFTMZLthVI7LE3rG0NWikNdCTe3ebul2bHXcvjHP3g9jHsfPzjJh_c_5MxbN3P6cppIqNI54DXdwFxulw4zW4XUsvD4EeeluSkwtoSYS0z-uoBejEtccznOalJKlMh2kwd31L5XSlF7u-XQXA3WlzW4m60uKwl4y__PeAe_uuBrgHfv4b3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2732485119</pqid></control><display><type>article</type><title>Pediatric antimicrobial stewardship in the COVID-19 outbreak</title><source>ProQuest Central Essentials</source><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>ProQuest Central</source><source>Cambridge University Press Journals Complete</source><creator>Velasco-Arnaiz, Eneritz ; López-Ramos, Maria Goretti ; Simó-Nebot, Silvia ; Jordan, Iolanda ; Ríos-Barnés, María ; Urrea-Ayala, Mireia ; Monsonís, Manuel ; Fortuny, Clàudia ; Noguera-Julian, Antoni</creator><creatorcontrib>Velasco-Arnaiz, Eneritz ; López-Ramos, Maria Goretti ; Simó-Nebot, Silvia ; Jordan, Iolanda ; Ríos-Barnés, María ; Urrea-Ayala, Mireia ; Monsonís, Manuel ; Fortuny, Clàudia ; Noguera-Julian, Antoni ; Kids Corona project</creatorcontrib><description>To the Editor—Growing evidence supports the positive impact of antimicrobial stewardship programs (ASPs) on antimicrobial use, including pediatrics.1 Although short of the level of acceptance these have reached in the United States, the implementation of pediatric ASPs in European hospitals has increased over the last few years.1 It has been suggested that the ASP should be helpful in the preparation for and response to the SARS-CoV-2/COVID-19 outbreak,2 but no formal recommendations have been published. From March 16 to April 30 2020, 210 randomly selected prescriptions were assessed for quality.3 Because SARS-CoV-2 is a viral infection, it is not expected to directly influence antibiotic or antifungal use beyond the use of antibiotics with possible antiviral effect (ie, azithromycin)4 and the use of broad-spectrum antibiotics for superinfection in severe COVID-19 patients.5 However, we also observed antimicrobial use changes indirectly related to the outbreak. New COVID-19 protocols are constantly updated in accordance with newly available information, and previous protocols have been temporarily modified in favor of medical nonsurgical management of some conditions (eg, noncomplicated appendicitis).7 Our data show that the SARS-CoV-2 pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population; pediatric ASP monitoring and interventions remain useful to preserve the quality of prescriptions, at least in the short term. Planning the response to epidemic waves should include the widespread integration of ASP, with (1) involvement of the ASP team in guidelines development as exemplified in “Multicenter Initial Guidance on Use of Antivirals for Children with COVID-19/SARS-CoV-2”8; (2) integrated response of common ASP local and external partnerships and infrastructures, including structured interviews, formularies, and other information technology tools9; and (3) coordination of indicator selection and monitoring routines to support a continuous evaluation strategy.</description><identifier>ISSN: 0899-823X</identifier><identifier>EISSN: 1559-6834</identifier><identifier>DOI: 10.1017/ice.2020.312</identifier><identifier>PMID: 32576298</identifier><language>eng</language><publisher>United States: Cambridge University Press</publisher><subject>Antibiotics ; Coronaviruses ; COVID-19 ; Disease prevention ; Information technology ; Letter to the Editor ; Nursing ; Outbreaks ; Pandemics ; Pediatrics ; Prescriptions ; Severe acute respiratory syndrome coronavirus 2 ; Young adults</subject><ispartof>Infection control and hospital epidemiology, 2021-05, Vol.42 (5), p.642-644</ispartof><rights>2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Society for Healthcare Epidemiology of America 2020 2020 The Society for Healthcare Epidemiology of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-90031d7b7b743c1a490eff90533d0bc82ab174ee38a2e95021f1f8e7960744703</citedby><cites>FETCH-LOGICAL-c536t-90031d7b7b743c1a490eff90533d0bc82ab174ee38a2e95021f1f8e7960744703</cites><orcidid>0000-0002-2400-3033</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2732485119/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2732485119?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,21388,21389,23256,27924,27925,33530,33531,33703,33704,33744,33745,43659,43787,43805,64385,64387,64389,72469,74104,74283,74302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32576298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Velasco-Arnaiz, Eneritz</creatorcontrib><creatorcontrib>López-Ramos, Maria Goretti</creatorcontrib><creatorcontrib>Simó-Nebot, Silvia</creatorcontrib><creatorcontrib>Jordan, Iolanda</creatorcontrib><creatorcontrib>Ríos-Barnés, María</creatorcontrib><creatorcontrib>Urrea-Ayala, Mireia</creatorcontrib><creatorcontrib>Monsonís, Manuel</creatorcontrib><creatorcontrib>Fortuny, Clàudia</creatorcontrib><creatorcontrib>Noguera-Julian, Antoni</creatorcontrib><creatorcontrib>Kids Corona project</creatorcontrib><title>Pediatric antimicrobial stewardship in the COVID-19 outbreak</title><title>Infection control and hospital epidemiology</title><addtitle>Infect Control Hosp Epidemiol</addtitle><description>To the Editor—Growing evidence supports the positive impact of antimicrobial stewardship programs (ASPs) on antimicrobial use, including pediatrics.1 Although short of the level of acceptance these have reached in the United States, the implementation of pediatric ASPs in European hospitals has increased over the last few years.1 It has been suggested that the ASP should be helpful in the preparation for and response to the SARS-CoV-2/COVID-19 outbreak,2 but no formal recommendations have been published. From March 16 to April 30 2020, 210 randomly selected prescriptions were assessed for quality.3 Because SARS-CoV-2 is a viral infection, it is not expected to directly influence antibiotic or antifungal use beyond the use of antibiotics with possible antiviral effect (ie, azithromycin)4 and the use of broad-spectrum antibiotics for superinfection in severe COVID-19 patients.5 However, we also observed antimicrobial use changes indirectly related to the outbreak. New COVID-19 protocols are constantly updated in accordance with newly available information, and previous protocols have been temporarily modified in favor of medical nonsurgical management of some conditions (eg, noncomplicated appendicitis).7 Our data show that the SARS-CoV-2 pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population; pediatric ASP monitoring and interventions remain useful to preserve the quality of prescriptions, at least in the short term. Planning the response to epidemic waves should include the widespread integration of ASP, with (1) involvement of the ASP team in guidelines development as exemplified in “Multicenter Initial Guidance on Use of Antivirals for Children with COVID-19/SARS-CoV-2”8; (2) integrated response of common ASP local and external partnerships and infrastructures, including structured interviews, formularies, and other information technology tools9; and (3) coordination of indicator selection and monitoring routines to support a continuous evaluation strategy.</description><subject>Antibiotics</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease prevention</subject><subject>Information technology</subject><subject>Letter to the Editor</subject><subject>Nursing</subject><subject>Outbreaks</subject><subject>Pandemics</subject><subject>Pediatrics</subject><subject>Prescriptions</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Young adults</subject><issn>0899-823X</issn><issn>1559-6834</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkc9r1UAQxxdR7Gv15lkCXjw0z5mdTXYXRJDnjxYK9aDibdkkE9_WvOR1N6n433dLa9EyhznMhy8z8xHiBcIaAfWb0PJagoQ1oXwkVlhVtqwNqcdiBcba0kj6cSAOU7oAAG0tPhUHJCtdS2tW4u0X7oKfY2gLP85hF9o4NcEPRZr5t49d2oZ9EcZi3nKxOf9--qFEW0zL3ET2v56JJ70fEj-_60fi26ePXzcn5dn559PN-7OyraieSwtA2Okml6IWvbLAfW-hIuqgaY30DWrFTMZLthVI7LE3rG0NWikNdCTe3ebul2bHXcvjHP3g9jHsfPzjJh_c_5MxbN3P6cppIqNI54DXdwFxulw4zW4XUsvD4EeeluSkwtoSYS0z-uoBejEtccznOalJKlMh2kwd31L5XSlF7u-XQXA3WlzW4m60uKwl4y__PeAe_uuBrgHfv4b3</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Velasco-Arnaiz, Eneritz</creator><creator>López-Ramos, Maria Goretti</creator><creator>Simó-Nebot, Silvia</creator><creator>Jordan, Iolanda</creator><creator>Ríos-Barnés, María</creator><creator>Urrea-Ayala, Mireia</creator><creator>Monsonís, Manuel</creator><creator>Fortuny, Clàudia</creator><creator>Noguera-Julian, Antoni</creator><general>Cambridge University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2400-3033</orcidid></search><sort><creationdate>20210501</creationdate><title>Pediatric antimicrobial stewardship in the COVID-19 outbreak</title><author>Velasco-Arnaiz, Eneritz ; López-Ramos, Maria Goretti ; Simó-Nebot, Silvia ; Jordan, Iolanda ; Ríos-Barnés, María ; Urrea-Ayala, Mireia ; Monsonís, Manuel ; Fortuny, Clàudia ; Noguera-Julian, Antoni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-90031d7b7b743c1a490eff90533d0bc82ab174ee38a2e95021f1f8e7960744703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease prevention</topic><topic>Information technology</topic><topic>Letter to the Editor</topic><topic>Nursing</topic><topic>Outbreaks</topic><topic>Pandemics</topic><topic>Pediatrics</topic><topic>Prescriptions</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Velasco-Arnaiz, Eneritz</creatorcontrib><creatorcontrib>López-Ramos, Maria Goretti</creatorcontrib><creatorcontrib>Simó-Nebot, Silvia</creatorcontrib><creatorcontrib>Jordan, Iolanda</creatorcontrib><creatorcontrib>Ríos-Barnés, María</creatorcontrib><creatorcontrib>Urrea-Ayala, Mireia</creatorcontrib><creatorcontrib>Monsonís, Manuel</creatorcontrib><creatorcontrib>Fortuny, Clàudia</creatorcontrib><creatorcontrib>Noguera-Julian, Antoni</creatorcontrib><creatorcontrib>Kids Corona project</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection control and hospital epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Velasco-Arnaiz, Eneritz</au><au>López-Ramos, Maria Goretti</au><au>Simó-Nebot, Silvia</au><au>Jordan, Iolanda</au><au>Ríos-Barnés, María</au><au>Urrea-Ayala, Mireia</au><au>Monsonís, Manuel</au><au>Fortuny, Clàudia</au><au>Noguera-Julian, Antoni</au><aucorp>Kids Corona project</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pediatric antimicrobial stewardship in the COVID-19 outbreak</atitle><jtitle>Infection control and hospital epidemiology</jtitle><addtitle>Infect Control Hosp Epidemiol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>42</volume><issue>5</issue><spage>642</spage><epage>644</epage><pages>642-644</pages><issn>0899-823X</issn><eissn>1559-6834</eissn><abstract>To the Editor—Growing evidence supports the positive impact of antimicrobial stewardship programs (ASPs) on antimicrobial use, including pediatrics.1 Although short of the level of acceptance these have reached in the United States, the implementation of pediatric ASPs in European hospitals has increased over the last few years.1 It has been suggested that the ASP should be helpful in the preparation for and response to the SARS-CoV-2/COVID-19 outbreak,2 but no formal recommendations have been published. From March 16 to April 30 2020, 210 randomly selected prescriptions were assessed for quality.3 Because SARS-CoV-2 is a viral infection, it is not expected to directly influence antibiotic or antifungal use beyond the use of antibiotics with possible antiviral effect (ie, azithromycin)4 and the use of broad-spectrum antibiotics for superinfection in severe COVID-19 patients.5 However, we also observed antimicrobial use changes indirectly related to the outbreak. New COVID-19 protocols are constantly updated in accordance with newly available information, and previous protocols have been temporarily modified in favor of medical nonsurgical management of some conditions (eg, noncomplicated appendicitis).7 Our data show that the SARS-CoV-2 pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population; pediatric ASP monitoring and interventions remain useful to preserve the quality of prescriptions, at least in the short term. Planning the response to epidemic waves should include the widespread integration of ASP, with (1) involvement of the ASP team in guidelines development as exemplified in “Multicenter Initial Guidance on Use of Antivirals for Children with COVID-19/SARS-CoV-2”8; (2) integrated response of common ASP local and external partnerships and infrastructures, including structured interviews, formularies, and other information technology tools9; and (3) coordination of indicator selection and monitoring routines to support a continuous evaluation strategy.</abstract><cop>United States</cop><pub>Cambridge University Press</pub><pmid>32576298</pmid><doi>10.1017/ice.2020.312</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-2400-3033</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0899-823X
ispartof Infection control and hospital epidemiology, 2021-05, Vol.42 (5), p.642-644
issn 0899-823X
1559-6834
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7338437
source ProQuest Central Essentials; ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; ProQuest Central; Cambridge University Press Journals Complete
subjects Antibiotics
Coronaviruses
COVID-19
Disease prevention
Information technology
Letter to the Editor
Nursing
Outbreaks
Pandemics
Pediatrics
Prescriptions
Severe acute respiratory syndrome coronavirus 2
Young adults
title Pediatric antimicrobial stewardship in the COVID-19 outbreak
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A44%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pediatric%20antimicrobial%20stewardship%20in%20the%20COVID-19%20outbreak&rft.jtitle=Infection%20control%20and%20hospital%20epidemiology&rft.au=Velasco-Arnaiz,%20Eneritz&rft.aucorp=Kids%20Corona%20project&rft.date=2021-05-01&rft.volume=42&rft.issue=5&rft.spage=642&rft.epage=644&rft.pages=642-644&rft.issn=0899-823X&rft.eissn=1559-6834&rft_id=info:doi/10.1017/ice.2020.312&rft_dat=%3Cproquest_pubme%3E2732485119%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2732485119&rft_id=info:pmid/32576298&rfr_iscdi=true